Download PDF
TumorDiagnostik & Therapie 2019; 40(09): 571-575
DOI: 10.1055/a-0961-9152
Schwerpunkt Harnblasenkarzinom
© Georg Thieme Verlag KG Stuttgart · New York

Systemtherapie des Harnblasenkarzinoms

Günter Niegisch
Further Information

Publication History

Publication Date:
17 October 2019 (online)

Also available at
    Permissions and Reprints

Eine Systemtherapie sollte bei geeigneten Patienten integraler Bestandteil der Behandlung des Harnblasenkarzinoms sein. Dieser Beitrag gibt eine Übersicht über die aktuellen Empfehlungen in der Erst- und Zweitlinie.
 

  • Literatur

  • 1 Madersbacher S, Hochreiter W, Burkhard F. et al. Radical cystectomy for bladder cancer today – a homogeneous series without neoadjuvant therapy. J Clin Oncol 2003; 21: 690-696
    CrossrefPubMedSearch in Google Scholar
  • 2 Hautmann RE, Gschwend JE, de Petriconi RC. et al. Cystectomy for transitional cell carcinoma of the bladder: results of a surgery only series in the neobladder era. J Urol 2006; 176: 486-492
    CrossrefPubMedSearch in Google Scholar
  • 3 Leow JJ, Martin-Doyle W, Fay AP. et al. A systematic review and meta-analysis of adjuvant and neoadjuvant chemotherapy for upper tract urothelial carcinoma. Eur Urol 2014; 66: 529-541
    CrossrefPubMedSearch in Google Scholar
  • 4 Seiler R, Ashab HAD, Erho N. et al. Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy. Eur Urol 2017; 72: 544-554
    CrossrefPubMedSearch in Google Scholar
  • 5 S3-Leitlinie Früherkennung, Diagnose, Therapie und Nachsorge des Harnblasenkarzinoms, Langversion 1.1, AWMF-Registernummer: 032/038OL. Stand November 2016 www.awmf.org/uploads/tx_szleitlinien/032-038ol_l_S3_Harnblasenkarzinom_2016-12.pdf
    PubMed
  • 6 Sternberg CN, de Mulder PH, Schornagel JH. et al. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors. J Clin Oncol 2001; 19: 2638-2646
    CrossrefPubMedSearch in Google Scholar
  • 7 von der Maase H, Hansen SW, Roberts JT. et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000; 18: 3068-3077
    CrossrefPubMedSearch in Google Scholar
  • 8 Galsky MD, Hahn NM, Rosenberg J. et al. Treatment of patients with metastatic urothelial cancer „unfit“ for Cisplatin-based chemotherapy. J Clin Oncol 2011; 29: 2432-2438
    CrossrefPubMedSearch in Google Scholar
  • 9 Niegisch G, Gerullis H, Lin SW. et al. A Real-World Data Study to Evaluate Treatment Patterns, Clinical Characteristics and Survival Outcomes for First- and Second-Line Treatment in Locally Advanced and Metastatic Urothelial Cancer Patients in Germany. J Cancer 2018; 9: 1337-1348
    PubMedSearch in Google Scholar
  • 10 De Santis M, Bellmunt J, Mead G. et al. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol 2012; 30: 191-199
    PubMedSearch in Google Scholar
  • 11 Grimm MO. Immunooncology in Urologic Cancers: Current Status. Akt Urol 2016; 47: 374-377
    Thieme ConnectPubMedSearch in Google Scholar
  • 12 Balar AV, Galsky MD, Rosenberg JE. et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet 2017; 389: 67-76
    CrossrefPubMedSearch in Google Scholar
  • 13 Balar AV, Castellano D, O’Donnell PH. et al. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol 2017; 18: 1483-1492
    CrossrefPubMedSearch in Google Scholar
  • 14 Bellmunt J, de Wit R, Vaughn DJ. et al. Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. N Engl J Med 2017; 376: 1015-1026
    CrossrefPubMedSearch in Google Scholar
  • 15 Rosenberg JE, Hoffman-Censits J, Powles T. et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 2016; 387: 1909-1920
    CrossrefPubMedSearch in Google Scholar
  • 16 Sharma P, Retz M, Siefker-Radtke A. et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol 2017; 18: 312-322
    CrossrefPubMedSearch in Google Scholar
  • 17 Powles T, Duran I, van der Heijden MS. et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2018; 391: 748-757
    CrossrefPubMedSearch in Google Scholar
  • 18 Bellmunt J, Theodore C, Demkov T. et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol 2009; 27: 4454-4461
    CrossrefPubMedSearch in Google Scholar
  • 19 Lam JM, Liu WK, Powles T. et al. Single-centre Experience of Patients with Metastatic Urothelial Cancer Treated with Chemotherapy Following Immune Checkpoint Inhibition. Eur Urol Oncol 2019;
    PubMedSearch in Google Scholar
  • 20 TCGA. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 2014; 507: 315-322
    PubMedSearch in Google Scholar